Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc., trading under the ticker OBIO, is a biomedical innovation company focused on developing medical device therapies, operating in the healthcare and medical devices sector. The company came to public markets through a merger with Health Assurance Acquisition Corp, a healthcare-focused SPAC that completed its IPO in 2020 and was sponsored by Health Assurance Acquisition Holdings LLC, a vehicle backed by a consortium of health system and insurance industry principals. The 10-Q/A filed on March 31, 2022, bearing accession number 0001213900-22-016917, represents an amended quarterly disclosure submitted during the pre-merger period. Orchestra BioMed's pipeline centers on cardiac neuromodulation and drug-coated balloon technologies. Visit SpacDesk and sign up for full filings history, sponsor data, and real-time deal tracking on OBIO and hundreds of other SPAC transactions.